Top Markets
Coin of the day
Vaxart, Inc. Vaxart, Inc.

Vaxart, Inc.

VXRT
Classement en actions #20724
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Prix de l'action
$0.5106
Capitalisation boursière
$123.59M
Changement (1 jour)
-1.81%
Changement (1 an)
45.89%
Pays
US
Échange Vaxart, Inc. (VXRT)

Catégorie

Ratio P/S pour Vaxart, Inc. (VXRT)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Vaxart, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Vaxart, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH